Literature DB >> 35485050

LINC00313/miR-4429 axis provides novel biomarkers for the diagnosis and prognosis of non-small cell lung cancer.

Jinxiang Wang1, Lihua Zhang1, Caihong Wang1, Yanfang Chen1, Xiaomei Sui1.   

Abstract

BACKGROUND: Increasing evidence suggests that the LncRNA/miRNA axis plays a key role in many types of tumorigenesis. However, the potential role and clinical value of LINC00313/miR-4429 in non-small cell lung cancer (NSCLC) remain elusive and need further study. The aim of this study was to investigate the role of LINC00313/miR-4429 axis in NSCLC.
METHODS: The expression of LINC00313 and miR-4429 in serum, tissues and cell lines of NSCLC patients were detected by reverse transcription-quantitative PCR. The diagnostic value was evaluated by receiver operating characteristic (ROC) curve analysis and the prognostic value was analyzed by Kaplan-Meier survival analysis and Cox regression. RESULT: The expression of LINC00313 was significantly up-regulated while the expression of miR-4429 was down-regulated in NSCLC serum, tissue and cell lines. A negative correlation was found between LINC00313 and miR-4429 in patients with NSCLC. ROC curves showed that LINC00313 and miR-4429 had high diagnostic value and Kaplan-Meier curve results showed that high expression of LINC00313 and low expression of miR-4429 predicted poor prognosis.
CONCLUSION: In summary, our data show that the ectopic expression of LINC00313 and miR-4429 has promising clinical significance in the diagnosis and prognosis of NSCLC. The LINC00313/miR-4429 axis may provide novel biomarker for NSCLC treatment.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35485050     DOI: 10.18388/abp.2020_5794

Source DB:  PubMed          Journal:  Acta Biochim Pol        ISSN: 0001-527X            Impact factor:   2.149


  1 in total

1.  Cancer cell-derived exosomal LINC00313 induces M2 macrophage differentiation in non-small cell lung cancer.

Authors:  Wencui Kong; Lei Zhang; Ying Chen; Zongyang Yu; Zhongquan Zhao
Journal:  Clin Transl Oncol       Date:  2022-08-18       Impact factor: 3.340

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.